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Abstract 
Parkinson’s disease (PD) is conventionally seen as resulting from single-system 
neurodegeneration affecting nigrostriatal dopaminergic neurons. However, ac-
cumulating evidence indicates a multi-system degeneration and neurotransmit-
ter deficiencies, including cholinergic neurons which degenerate in a brainstem 
nucleus, the pedunculopontine nucleus (PPN), resulting in motor- and cognitive 
impairments. The neuropeptide galanin can inhibit cholinergic transmission, 
whilst being upregulated in degenerating brain regions associated with cognitive 
decline. Here we determined the temporal-spatial profile of progressive expres-
sion of endogenous galanin within degenerating cholinergic neurons, across the 
rostro-caudal axis of the PPN, by utilising the lactacystin-induced rat model of 
PD. First, we show progressive neuronal death affecting nigral dopaminergic and 
PPN cholinergic neurons, reflecting that seen in PD patients, to facilitate use of 
this model for assessing the therapeutic potential of bioactive peptides. Next, 
stereological analyses of the lesioned brain hemisphere found that the number of 
PPN cholinergic neurons expressing galanin increased by 11%, compared to 
sham-lesioned controls, increasing by a further 5% as the neurodegenerative 
process evolved. Galanin upregulation within cholinergic PPN neurons was most 
prevalent closest to the intra-nigral lesion site, suggesting that galanin upregula-
tion in such neurons adapt intrinsically to neurodegeneration, to possibly neuro-
protect. This is the first report on the extent and pattern of galanin expression in 
cholinergic neurons across distinct PPN subregions in both the intact rat CNS and 
lactacystin lesioned rats. The findings pave the way for future work to target 
galanin signaling in the PPN, to determine the extent to which upregulated 
galanin expression could offer a viable treatment strategy for ameliorating PD 
symptoms associated with cholinergic degeneration.  
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Introduction 
Galanin is a 29-amino acid (aa) long (30 aa long in humans) neuropeptide en-
coded for by the GAL gene (Tatemoto et al. 1983). It is widely distributed in the 
brains of rodents (Skofitsch and Jacobowitz 1985; Melander et al. 1986), non-
human primates (Kordower et al. 1992) and humans (Le Maître et al. 2013; 
Gentleman et al. 1989), where it helps regulate several physiological processes, 
including aspects of cognition, food intake, nociception and sexual behaviour 
(Vrontakis 2002; Ogren et al. 2010). Expression levels of galanin and galanin 
receptors were shown to be altered in the brains of patients diagnosed with neu-
rological disorders, including Alzheimer’s disease (AD) (Beal et al. 1990) and 
multiple sclerosis (Wraith et al. 2009). In addition, a study by Chan-Palay 
(1988) showed that in AD post-mortem brains, severe hypertrophy affects a 
network of neuronal axons expressing galanin (especially those based within the 
anterior part of the nucleus basalis of Meynert (nbM)), which innervate the basal 
cholinergic neurons (termed hyperinnervation). Based on these findings, Alexan-
dris and others (2015) conducted post-mortem analyses of the nbM taken from 
patients who suffered from Lewy body disorders (LBD), but with no concurrent 
AD pathology, to calculate the innervation scores of fibres containing galanin. 
LBD is clinically separated into Parkinson’s disease (PD), PD with dementia 
(PDD), and dementia with Lewy bodies (DLB), based on the severity of cognitive 
dysfunction a patient presents with, and on the temporal sequence by which 
cognitive- versus motor symptoms appear to manifest (Mrak and Griffin 2007). 
The study reported that in LBD patients, galanin innervation was increased, and 
that galanin expression occurred within the soma of neurons based in the nbM. 
As indicated, studies suggest that an intricate functional relationship exists 
between galanin and the neurotransmitter acetylcholine (ACh) (Chan-Palay 
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1988; Crawley and Wenk 1989). However, conflicting findings have been report-
ed as to whether galanin signaling benefits or acts deleteriously on the function-
ing and survival of cholinergic neurons in the brains of patients suffering from 
neurodegenerative disease. For instance, Counts and others (2006) analyzed 
post-mortem anterior nucleus basalis samples taken from AD patients that had 
been categorized into three diagnostic groups, namely patients that had been 
diagnosed as having no cognitive impairment, those with mild cognitive impair-
ment, and those with early-stage (mild/moderate) AD. Across the three sub-
groups of AD patients, the investigators detected no difference in the degree to 
which galanin-containing axons innervated remaining cholinergic basal forebrain 
neurons. In addition, the study reported that remaining cholinergic neurons 
within the nucleus basalis expressed mRNA for all three galanin receptor sub-
types identified so far; however, similar levels were measured for all three diag-
nostic subgroups. Hence, this work showed that galanin-containing axons are 
not hypertrophied during the prodromal or early stages of AD, but that galanin 
fiber enlargement seems to rather manifest during late-stage AD, as reported 
previously (Chan-Palay et al. 1988; Bowser et al. 1997). Hyperinnervation by 
such hypertrophied neurons may play a crucial role in regulating the cholinergic 
tone of the basocortical cholinergic system, the integrity which is structurally 
and functionally compromised in AD. 
In other work, Steiner et al. (2001) reported that galanin overexpression 
impairs learning and memory in mice. The study’s additional finding, that 
galanin overexpression associated with a significant reduction in the number of 
cholinergic neurons in these animals, suggests that galanin overexpression is 
harmful to the survival and function of cholinergic neurons. On the other hand, 
there is considerable support for the notion that galanin may counteract cholin-
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ergic degeneration, with Ding and colleagues (2006) who reported that galanin 
protects cholinergic basal forebrain neurons against AD-related amyloid-β	(Aβ) 
toxicity. The notion that galanin is neuroprotective was corroborated by Pirondi 
and others (2009), who demonstrated in cholinergic SN56 neuroblastoma cells 
that Gal2-11, a galanin receptor 2/3 subtype agonist, abolished Ab-induced 
apoptotic DNA fragmentation and that the neuroprotection was mediated 
through a reduction of caspase-3 mRNA expression. Similarly, in other work, El-
liot-Hunt and colleagues (2011) showed that Ab1-42 peptide induced a significant-
ly greater degree of cell death in mice harboring loss-of-function mutations in 
galanin or galanin receptor 2 (GAL2), and that this was reduced in galanin over-
expressing transgenic mice, in each case compared to strain-matched wild-type 
control mice. In neonatal hippocampal neurons taken from these transgenic 
mice, exogenous galanin or Gal2-11 fully rescued deficits in galanin knock-out, 
but not in GAL2 cultures that lack a functional GAL2, confirming that galanin’s 
protective effects are mediated by activation of GAL2. Taken together, several 
studies have demonstrated that both exogenous galanin and neuronal upregula-
tion of galanin is neuroprotective against neurodegeneration, implying that de-
velopment of galanin agonists might have a role as potential neuroprotective 
therapies against neurodegenerative disease.  
Galanin is expressed within neurotransmitter inputs to the pedunculopontine 
nucleus (PPN), located in the caudal pontomesencephalic tegmentum of the ros-
tral brainstem (Gai et al. 1993), where it regulates diverse functions, including 
locomotion (Moro et al. 2010; Pienaar et al. 2015a, b), cognitive functions such 
as attention, learning and working memory (Taylor et al. 2004; Faure et al. 
2014), as well as arousal and sleep-wake transitions (Datta and Siwek 2002; 
Hobson and Pace-Schott 2010). Although disruption of voluntary motor control, 
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a prominent clinical feature of PD, is thought to be due to dopaminergic patho-
physiology, evidence is growing that certain motor and non-motor comorbidities 
seen in PD patients are likely to arise from progressive degeneration of the cho-
linergic PPN (Hirsch et al. 1987; Rinne et al. 2008; Pienaar et al. 2013). 
Considering the limited number of studies which have reported on galanin-
cholinergic interactions in PD-affected brains, we made use of rats that had been 
intranigrally and unihemispherically lesioned with the irreversible ubiquitin pro-
teasome system inhibitor, lactacystin. The lactacystin rat model recapitulates 
several neuropathological features of PD, including degeneration of the nigrostri-
atal system (Pienaar et al. 2015a; 2015b) and PPN cholinergic neurons 
(McNaught et al. 2002; Pienaar et al. 2015a; 2015b; Elson et al. 2016), intra-
cytoplasmic accumulation of altered proteins within remaining neurons 
(McNaught et al. 2002; Pienaar et al. 2015a; Elson et al. 2016), PD-related mo-
tor abnormalities (Pienaar et al. 2015a; 2015b;Elson et al. 2016), as well as an 
inflammatory reaction (Elson et al. 2016). The animals were grouped into those 
sacrificed at 8 days following surgery (acute stage) and those sacrificed at 35 
days post-surgery (chronic stage), to characterize the temporal- and spatial ex-
pression profile of intrinsic galanin, from the intra-nigral site of the toxin’s injec-
tion, to then spread across the rostro-caudal axis of the PPN. We performed this 
extensive characterization in order to better understand whether an alteration of 
endogenous galanin expression could be regarded as a response to neurodegen-
eration of PPN cholinergic neurons, potentially aimed at preserving the remain-
ing pool of such neurons.  
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Materials and Methods 
Animals 
Male, adult (250g) Sprague-Dawley rats (n = 30) were used for the current ex-
periments and kept under controlled environmental conditions (24–25°C; hu-
midity 50–60%; 12h dark/light cycle) with free access to tap-water and food. 
Imperial College London’s ethics review panel accepted all experimental proto-
cols, with all experiments that were performed in line with the Animals (Scien-
tific Procedures) Act 1986 (UK).  
Surgeries and Pharmacological Validation of Nigral Lesion Size  
Neurotoxic lactacystin lesions of the Substantia Nigra pars compacta (SNpc) 
were performed whilst the rats (n = 18) were deeply anesthetized with Isoflu-
rane (Isoflo Abbot Laboratories Ltd., UK), which was vaporised into O2 and initi-
ated at a delivery flow-rate of 2 L/min. Following the standard procedure for 
preparing the animal for surgery, the SNpc was stereotaxically injected as previ-
ously described (Pienaar et al. 2015a; 2015b; Elson et al. 2016). In brief, a den-
tal drill was used to drill a small burr hole through the cranium over the left 
SNpc, using the coordinates: 5.2 mm (anterior–posterior) and 2.4 mm (medio-
lateral), relative to bregma (Paxinos and Watson 2009). Each rat in the lesioning 
group received 10µg of lactacystin (Enzo Life Sciences, UK), dissolved in 2.5 µl 
isotonic sterile 0.9% saline (pH 7.4). A total of 4 µl of the lactacystin solution 
was infused into each rat. The solution was prepared immediately prior to deliv-
ery by diluting the stock solution, which was stored on ice to prevent degrada-
tion. The lactacystin dose given here is similar to that used in several other 
studies (e.g. Mackey et al. 2013; Vernon et al. 2010; Harrison et al. 2015; 
Pienaar et al. 2015a; 2015b; Elson et al. 2016), and was well tolerated by the 
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rats, resulting in no mortalities. Sham-lesioned rats (n = 12) received an equal 
volume of sterile saline only. 
The intra-nigral infusion was delivered via a blunt-tipped 10 µl (32-G) Hamil-
ton glass syringe (700 series, VWR International, Denmark), at a rate of 1 
µl/min, which was driven by a microinjector syringe pump (11 Plus Elite, Har-
vard Apparatus, USA), at a depth of -7.6 mm (ventral-dural, relative to the dural 
surface of the brain). The needle was left in situ for an additional 5 min before 
slowly retracting from the brain. Aseptic conditions prevailed throughout all sur-
gical procedures. Following surgery, the scalp was sutured and topical antibacte-
rial ointment (Topazone, Austin Laboratories, Canada) was applied. The rats 
were left to fully recover in a heated recovery chamber, which included providing 
fluid replacement therapy, before being returned to their main cages. Analgesic 
(Meloxicam, 1mg/kg intraperitoneally (i.p.), Boehringer Ingelheim, Germany) 
was administered daily until an animal had fully recovered, based on grooming 
and overall appearance, including having returned to their pre-surgery weight. 
Sutures were removed 7-10 days post-surgery. 
In order to assess the efficacy of the lactacystin-induced SNpc lesion and to 
confirm the absence of SNpc damage in sham-lesioned animals, all rats were as-
sessed for amphetamine-induced rotation bias at 7 days post-surgery. Testing 
was performed during the dark portion of the light cycle by an assessor blind to 
the treatment condition, so as not to introduce bias. In rats, systemic application 
of D-amphetamine enhances dopamine (DA) content at striatal dopaminergic 
nerve terminals (Robinson and Becker 1982). In turn, dose-dependent D-
amphetamine-induces dose-dependent differences in DA content between the 
two cerebral hemispheres which in turn produces rotations away from the le-
sioned side, where the greatest level of DA signaling occurs (Glick et al. 1981). 
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D-amphetamine (5 mg/kg, Sigma-Aldrich, UK) was administered i.p. to the rats 
at a dose of 1 ml/kg, dissolved in 0.9% sterile saline. At 30 min post-injection, 
an animal was placed in a Perspex circling bowl (height: 360mm, diameter: 
400mm) and the net number of turns made in a contralateral and ipsilateral di-
rection was counted over a 30 min period. Sham-lesioned control rats were simi-
larly assessed to confirm the absence of a nigral lesion and sacrificed at similar 
time-points to that of the toxin-lesioned animals. 
Rats were sacrificed either at 8 (Time (T)1) or 35 days (T2) following lesion-
ing with the toxin (T1: n = 9, T2: n = 9) or sham surgery (T1: n = 6, T2: n = 
6), via injection with a lethal dose of sodium pentobarbital (100 mg/kg, i.p.), be-
fore transcardial perfusion with 50 ml heparinized phosphate-buffered saline 
(PBS) at 37°C, followed by 4% paraformaldehyde (PFA) in PBS (pH 7). Rats’	
brains were then removed, with each brain that was post-fixed in the same fixa-
tive solution for 48h, followed by cryopreservation in 30% sucrose in PBS. The 
brains were then snap-frozen in isopentane that had been pre-chilled on dry ice 
and stored at -80°C until serial cryostat sectioning at 30 µm thickness, in the 
coronal plane. The sections were thaw mounted onto Super Frost Plus histologi-
cal slides (Fisher Scientific, USA) with slides stored at -80°C until histological 
processing. Cresyl fast violet (CFV) staining was used to confirm infusion needle 
placements, using staining procedures similar to those previously de-
scribed (Elson et al. 2016; Pienaar et al. 2015a).  
Lactacystin-lesioned rats were included in the study if D-amphetamine in-
duced a minimum of 7 ipsilateral complete rotations/min. Out of 18 toxin-
lesioned rats, 16 were selected for the present study, based on their ipsilateral 
D-amphetamine-induced rotation scores. Of these 16, a further 2 were excluded 
due to poor stereotaxic needle placement, according to the analysis of the CFV-
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stained brain sections. Therefore, the statistical analysis of the stereology data 
presented in the present study is based on a total; of 14 lesioned rats (T1: n = 
7, T2: n = 7) and 12 sham-lesioned control ones (T1: n = 6, T2: n = 6).  
Immunohistochemistry and Immunofluorescence 
Dopaminergic neurons in the SNpcs of both toxin- and sham-lesioned rats, sacri-
ficed at both T1 and T2, were identified immunohistochemically by staining for 
the enzyme tyrosine hydroxylase (TH), the rate-limiting enzyme accountable for 
DA synthesis (reviewed by Daubner et al. 2011). The sections were dewaxed, 
hydrated, dehydrated and mounted as previously described (Pienaar et al. 
2015a, b). Similarly, the sections were incubated for 60 min at room tempera-
ture (RT) with a polyclonal primary antibody raised against TH (1:1,000 anti-
rabbit; Pel-Freez Biologicals, USA), diluted in 20% normal goat serum in PBS, 
followed by incubation with the secondary antibody (1:200, biotinylated goat an-
ti-rabbit; Vector Laboratories, USA) for 2h at RT. Antigen/primary-antibody 
complex binding was detected using a commercially available kit for detecting 
streptavidin–biotin–peroxidase substrate (Vectastain, Vector Laboratories, 
Burlingame, CA, USA) and visualized by applying 33’-diaminobenzidine (DAB, 
Vector Laboratories) for 8-10 min at RT.  
Cholinergic neurons of the rat PPN were immunofluorescently double-stained 
for choline acetyltransferase (ChAT), the rate-limiting enzyme in the biosynthetic 
pathway for ACh (Lipton 1946) and for galanin. After drying out the sections 
overnight at RT, the sections were hydrated in a graded ethanol (EtOH) series 
and then washed in distilled water. Endogenous peroxidase was quenched for 20 
min by exposing the sections to 0.3% H2O2 in 0.1 M tris buffered saline (TBS). 
Antigen retrieval was performed by heating the sections for 5 min in boiled citric 
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acid buffer solution (2 mM/L citric acid, 9 mM/L trisodium citrate dehydrate, pH 
6.0), followed by applying 10% normal donkey serum to the sections for 60 min 
at RT, to block non-specific binding. The blocking solution was discarded before 
the primary antibodies were simultaneously applied for detecting ChAT- (1:150 
polyclonal goat, AB144P; Invitrogen, USA) and galanin-immunoreactive (ir) neu-
rons (1:2,000 polyclonal rabbit, AB2233; Merck Millipore, USA). The sections 
were left to incubate overnight in the antibody solution at 4°C. The following 
day, the sections were washed in PBS (3 x 5 min) before incubating for 2h at RT 
in a solution containing the secondary antibodies. These were Alexa Fluor 568-
conjugated donkey anti-goat (1:200, Vector Laboratories) for identifying ChAT-ir 
neurons and Alexa Fluor 488-conjugated donkey anti-rabbit (1:200, Vector La-
boratories) for revealing galanin-ir ones. The sections were then immersed for 5 
min in a freshly filtered solution of 0.5% Sudan Black B (Sigma-Aldrich, UK), 
prepared as a saturated solution in 70% EtOH (Pienaar et al. 2015c). Sudan 
Black B treatment is a widely used method by which to reduce autofluorescence 
(Oliveira et al. 2010). Sections were then rinsed under running tap water, fol-
lowed by a final rinse in PBS (3 ×	5 min), before mounting under a coverslip us-
ing an aqueous mounting medium containing the nuclear dye 4’,6-diamidino-2-
phenylindole (DAPI) (DAKO, Germany). For all stains, negative control sections 
from each animal underwent identical staining preparation, except that 
the primary or secondary antibodies were omitted. All antibody and serum dilu-
tions were made in TBS. 
To evaluate the quality of the immune reactions and allow for consistency 
between batches of stained brain tissue sections, at least 2 stained slides per re-
action (TH and ChAT-galanin-DAPI) per animal were visually inspected with the 
aid of either an optical microscope (for viewing TH-stained sections) or confocal 
 	 12 	
imaging (for viewing ChAT-galanin-DAPI-stained sections). To further ensure 
that the antibody binding was specific, microscope-aided visual inspection was 
carried out for each animal on 2 negative control slides, one where the primary 
antibody had been omitted, whilst the secondary antibody had been omitted in 
the other.  
High-magnification (20×	air-immersion objective lens) photomicrographs 
was captured with a digital camera (Optronics, 1200 × 1660 pixels) coupled to 
an AxioImager M2 microscope (Carl Zeiss Ltd., Heidelberg, Germany) of the TH-
stained sections. The images were recorded using a charge-coupled device 
(CCD) colour video camera (1200 × 1660 pixels, Optronics, Goleta, CA, USA), 
fitted with a zoom lens and linked to a desktop computer. The captured images 
were saved with Northern Eclipse image software (v8.0, Empix Imaging Inc., 
Mississauga, Canada). Analysis at high magnification (Fig. 1A) revealed that in 
the SNpc of control rats, TH-ir neurons that had been immunolabelled using the 
DAB-peroxidase system, presented with a brown immune-positive soma as well 
as axonal and dendritic processes, similar to previous reports (Nair-Roberts et 
al. 2008). Figure 1A is a representative image of a DAB-stained brain section 
showing the SNpc of a sham-lesioned control rat. 
PPN rat brain sections where cholinergic neurons have been co-stained for 
galanin and counterstained with DAPI, were viewed with a TCS SP5 II confocal 
laser scanning microscope (Leica Microsystems, Wetzlar, Germany) under 20×	
magnification. The images were digitally viewed with LAS EZ image analysis 
software (Leica Microsystems) and merged automatically using built-in functions 
in Adobe Photoshop (version 7.0). Figure 1B shows a representative digital im-
age of a fluorescently-stained ChAT-galanin-DAPI PPN brain section, derived 
from a lactacystin-lesioned rat. The reaction for the ChAT-galanin neurons over-
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lapped completely (an unquantified observation). Clear galanin-immunoreactivity 
was only observed in lactacystin-lesioned animals, with very low levels of 
galanin-immunoreactivity that was seen in the PPN of rats that had not been le-
sioned with the neurotoxin; these observations are reflected in the stereology 
results presented below. Interestingly, a subpopulation of neuronal cells ex-
pressing galanin did not co-express ChAT (Fig. 1B), indicating galanin localiza-
tion within non-cholinergic neurons of the PPN, to further contribute to the no-
tion of the PPN as a highly heterogeneous structure. This aspect will be dis-
cussed further below.  
Stereological Neuronal Counts 
To quantify ChAT-ir neurons that co-localized with galanin-ir ones in the rat PPN 
and also to determine the number of TH-ir neurons in the SNpc of the rat brains, 
the unbiased optical fractionator method for stereological cell quantification was 
used (West et al. 1991). Stereological estimates were made in the lesioned and 
non-lesioned brain hemispheres within the structures of interest (SNpc and PPN) 
of lactacystin-lesioned rats compared to sham-lesioned control rats, using a 
computer-based stereology software system (Image-Pro®	Plus, Media Cybernet-
ics, Rockville, USA) attached to a Nikon Eclipse E800 motorized microscope and 
a live video camera (JVC 3CCD KY-F55B; JVC Ltd., Yokohama, Japan). The SNpc 
was distinguished from the substantia nigra pars reticulata (SNr), the ventral 
tegmental area (VTA) and the retrorubral area by consulting published guide-
lines on anatomical landmarks and regional differences in cell density orientation 
(Baquet et al. 2009; Oorschot 1998; Paxinos and Watson 2009). In the sham-
lesioned rats, the PPN was identified on the ChAT-stained sections by the PPN’s 
characteristic wedge-like shape, formed by the Ch5 cholinergic neuronal popula-
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tion (Mesulam et al. 1983; 1989). Due to neuronal loss, this shape was disrupt-
ed in toxin-lesioned rats; however, sufficient numbers of cholinergic neurons 
remained to form a recognizable cholinergic neuronal nucleus. Anatomical land-
marks that provided additional guidance to identify the PPN (Paxinos and Watson 
2009). In this regard, the PPN’s rostral boundary consists of the SNr, with the 
PPN that extends dorso-caudally towards the lateral tip of the superior cerebellar 
peduncle, at 60°	from a vertical line (Pienaar and Van de Berg 2013; Mena-
Segovia et al. 2009). The PPN-Ch5 cell group was distinguished from a neighbor-
ing cholinergic cell group (Ch6), which defines the laterodorsal tegmental nucle-
us (LDTg), by referring to a rat brain atlas (Paxinos and Watson 2009).  
Of every 6th section, a tiled image was taken at x4 magnification. In this im-
age, the ipsilateral and contralateral SNpc and PPN were delineated manually. 
The total area of the counting frames, relative to the area of the respective area 
of interest (AOI) provides the area sampling fraction (asf). Using the uniform 
systematic random sampling method with a sampling fraction of 2, the computer 
system placed counting frames (140 x 160 µm) across the whole of the AOI. The 
number of TH-ir neurons in each of the counting frames was then counted at 
x10 magnification, whereas the ChAT-galanin-ir neurons were counted at x20 
magnification. To eliminate edge effects, “acceptance”	and “forbidden”	lines were 
used: Cells crossing either the east or north borders were included in the count, 
whereas cells crossing either the south or west borders were ignored. The height 
of the sampling fraction (hsf) was calculated for each section by using a micro-
cator (MT-12, Heidenhain, Germany), which measures the average height of the 
counted optical plane relative to the section thickness. For each section the 
number of TH-ir and ChAT-ir neurons was then calculated using the equation: N 
= n(1/ssf)(1/asf)(1/hsf), where n equals the number of positive cells counted 
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and ssf refers to the section sampling fraction. In our case, the ssf was1/6, as 
we analysed every 6th section throughout the AOI.  
Statistical Analyses 
Statistical analyses were performed by using the Statistical Package for Social 
Sciences (SPSS) software programme (Version 20, IBM Corp., Chicago, USA) 
with the limit for statistical significance set at 0.05. The following p-value desig-
nations were applied: ***P < 0.001, extremely significant; **P	≤	0.01, highly 
significant; *P	≤	0.05, significant and P > 0.05, non-significant (n/s). For analys-
ing the SNpc TH-ir neuronal stereology data, a one-way ANOVA was applied to 
compare the neuronal densities counted within the PPNs of the two brain hemi-
spheres in the different treatment groups, representing both assessment time-
points, followed by a Tukey post-hoc comparison. A two-way ANOVA followed by 
a Tukey post-hoc comparison test was used for analysing the PPN ChAT-ir neu-
ronal stereology data to consider for the effects of time and distance away from 
the SNpc on the sham- and toxin-lesioned rats. The results are expressed as the 
mean value ±	the standard error of the mean (SEM). 
Results  
Validation of the Dopaminergic Nigrostriatal Lesion 
At 30 min following D-amphetamine administration, 16 out of 18 lactacystin-
lesioned animals rotated exclusively in an ipsiversive direction. These 16 rats 
were then randomly divided into 2 groups, those representing an acute stage (n 
= 7 (121 ± 23 complete turns)), and those representing a chronic stage (n = 7 
(114 ± 15 complete turns)) of experimental parkinsonism, at which respective 
time-point the brains were collected for stereological evaluation. 
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None of the sham-lesioned rats (n = 12) revealed biased D-amphetamine-
induced rotational behaviour post-surgery. Stereological neuronal counts of TH-ir 
SNpc for sham-lesioned control rats sacrificed at the first time-point (n = 6) re-
vealed similar SNpc dopaminergic neuronal counts between the 2 hemispheres 
(ipsilateral side: 11,742 ±	378; contralateral side: 11,976 ±	296; Figs. 2Ai, B), 
translating to a very small overall inter-hemispheric difference of 1.95% (P 
=0.83, n/s; Fig. 2B). Similarly, at the chronic assessment time-point (n = 6), 
difference between the control rats’	stereological TH-ir neuronal counts in the ip-
silateral (13,151 ±	239) and contralateral SNpc (13,241 ±	239) accounted for 
only a 0.68% difference (n/s, P =0.99; Figs. 2Aii, B). 
In lactacystin-lesioned rats sacrificed at the acute time-point (n = 7), the 
non-injected hemisphere’s SNpc contained 11,704 ±	164 TH-ir neurons, while 
the toxin-injected SNpc contained only 7,276 ±	227 TH-ir neurons, the inter-
hemispheric difference of 37.98%, which represented a statistically significant 
neuronal loss (***P < 0.0001; Figs. 2Ai, B). At the chronic time-point (n = 7), a 
highly significant TH-ir neuronal loss was again detected between the 2 hemi-
spheres (***P < 0.0001; Figs. 2Aii, B), with a density count of 11,568 ±	229 for 
the SNpc on the non-injected hemispheric side compared to 6,467 ±	390 on the 
toxin-injected hemispheric side, representing a difference of 44.1%. A compari-
son between the TH-ir neuronal densities of the injected hemispheric side of tox-
in-lesioned rats, culled at 8 days- and 35 days post-surgery, did not reveal a 
statistically significant difference (P =0.149, n/s).  
Taken together, the data suggests that in this in vivo rat model of PD, a rap-
id loss of SNpc TH-ir neurons occurs within a short time-period following the in-
tranigral infusion of lacytacystin, with a relatively stable population of resistant 
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neurons that remained, subsequent to the initial insult and up to 35 days follow-
ing the intra-nigral toxin infusion.    
Stereological Cell Counts and Topological Distribution Profile of PPN 
ChAT-ir Neurons 
The panel of images shown in Figure 3 of ChAT-ir neurons in the PPN under both 
toxin and sham-control conditions, represent progressively posterior anatomical 
levels along the rostro-caudal axis of the PPN. The images illustrate the signifi-
cantly greater overall loss of such neurons at the later stage of the lesion, com-
pared to the acute stage. The images also show that this greater loss of ChAT-ir 
PPN neurons which were noted to have occurred at the later time following the 
lesion, is largely due to time-dependent spreading of the lactacystin-induced 
damage and destruction of neurons. Thus, lactacystin decreases the number of 
PPN ChAT-ir neurons located in the most rostral (nearest to the intranigral injec-
tion site) PPN region, to then gradually also impact upon the cholinergic neurons 
of the medial and (even later) the caudal PPN sections.  
Stereological cell counts were made of the ChAT-ir PPN neurons on the ipsi-
lateral and contralateral hemispheric sides in the lactacystin- and sham-lesioned 
rat brains at both time-points. On the ipsilateral hemispheric side of control rats 
culled at the “acute”	assessment stage (n = 6), 3,130 ±	43 neurons were rec-
orded, with 3,154 ±	44 on the contralateral hemispheric side. As to the rats 
where the sham lesion was allowed to progress up to 35 days post-surgery (n = 
6), the density values of cholinergic neurons were: ipsilateral hemisphere: 3,029 
±	51; contralateral hemisphere: 3,062 ±	53. In contrast, the following ChAT-ir 
neuronal densities were recorded in toxin-lesioned rats’	PPN: ipsilateral hemi-
sphere: 2,475 ±	38; contralateral hemisphere: 3,005 ±	80 (acute stage, n = 7); 
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ipsilateral hemisphere: 2,017 ±	70; contralateral hemisphere: 3,050 ±	50 
(chronic stage, n = 7). 
In sham-lesioned rats, a two-way ANOVA detected no statistically significant 
difference between ipsilateral and contralateral PPN ChAT-ir neuronal counts 
when the data sets that represent either the first (n = 6) or the second post-
surgical evaluation time-point (n = 6) were considered (Fig. 4A). On the other 
hand, for the lactacystin-lesioned rats a highly significant difference (***P < 
0.0001) was seen in terms of cholinergic neuronal loss when the ipsilateral and 
contralateral hemispheres were compared at the earlier (n = 7) and also the lat-
er time-point (n = 7) (Fig. 4A). 
Previous work that analysed the topological distribution profile of ChAT-ir 
neurons in the non-lesioned (intact) PPN of rats revealed a characteristic rostro-
caudal density gradient, with a higher density of such neurons seen in the caudal 
segments of the nucleus compared to the rostral ones (Mena-Segovia et al. 
2009; Pienaar et al. 2015a; 2015b; Elson et al. 2016). Similar to these reports, 
the current study revealed an overall significant effect when a comparison was 
drawn between the cholinergic neuronal density values of the PPN from the most 
rostral sections, transitioning to the caudal end of the nucleus (***P < 0.0001). 
Time (in days) since surgery produced no significant effect on the regular ChAT-
ir neuronal density pattern in the sham-lesioned rats (P =0.97, n/s). To investi-
gate the effect of the toxin, the ipsilateral (injected) hemisphere of the lactacys-
tin-lesioned rats was compared to the sham-lesioned ones by applying a section-
by-section analysis, i.e. for the acute lesion cohort: section (S)1 of lactacystin-
lesioned rats compared to S1 of sham-lesioned ones; for the chronic lesion co-
hort: S1 of lactacystin-lesioned rats compared to S1 of sham-lesioned rats, etc. 
(Fig. 4B, see insert). Analysis done on the ipsilateral PPN ChAT-ir neuronal den-
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sities of rats sacrificed at the first assessment time-point revealed that S1 and 
S2 (***P < 0.0001), S3 (*P =0.039) and S4 (***P < 0.0001) differed signifi-
cantly between sham control and toxin-lesioned rats with S5 (P =0.068, n/s) 
showing a value of borderline significance. None of the more caudal sections 
(>S5) showed a notable difference in neuronal density between the two rat 
groups (Fig. 4B). However, in rats that had been sacrificed 35 days following 
toxin injection, the following differences were recorded: S1 (***P =0.0001), S2 
(**P =0.007), S3 (***P =0.0001), S4 (**P =0.002), S5 (*P =0.046), S6 (P 
=0.066, n/s) and S9 (**P =0.004) (Fig. 4C), indicating that, as time since le-
sioning progresses, the toxin impacts upon the more caudal PPN segments in 
rats. 
Stereological Cell Counts and Topological Distribution Profile of PPN 
ChAT-Galanin -ir Neurons 
The representative low-magnification microscopic image shown in Figure 5, tak-
en of neurons that had been dual immunofluorescently stained for ChAT and 
galanin, revealed the relatively sparse ChAT-galanin co-expressing neurons in 
the rat PPN, under non-toxic conditions. However, the images reveal the dra-
matic upregulation of the number of PPN cholinergic neurons co-expressing 
galanin in the lactacystin rat model of PD, compared to sham-lesioned controls. 
The densities of ChAT- and galanin-ir co-expressing neurons were examined in 
both the non-lesioned contralateral and lesioned ipsilateral hemispheres of the 
lactacystin- and control rats for both assessment time-points. As expected, simi-
lar neuronal densities were seen on the non-injected/contralateral hemispheric 
sides of sham- (acute stage (n = 6): 314 ±	7; chronic stage (n = 6): 272 ±	10) 
compared to lactacystin-lesioned rats (acute stage (n = 7): 283 ±	7; chronic 
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stage (n = 7): 299 ±	12) for both assessment time-points, the difference in each 
case being statistically n/s (acute stage: P = 0.14, n/s; chronic stage: P = 0.72, 
n/s) (Fig. 6A). In contrast, analysis of ChAT-galanin-ir neuronal densities of the 
PPN on the sham/lactacystin injected hemispheric side revealed significant dif-
ferences when comparing sham- (acute stage (n = 6): 325 ±	6; chronic stage (n 
= 6): 301 ±	11) to toxin-lesioned rats (acute stage (n = 7): 532 ±	15; chronic 
stage (n = 7): 534 ±	30), revealing extremely statistically significant differences 
for both assessment time-points (***P < 0.0001; Fig. 6A). However, from the 
first to the second lesion development time-point, a slightly lower, but not nota-
ble, overall decrease of PPN ChAT-galanin-ir neuronal densities was measured on 
the lesioned hemispheric sides of toxin-lesioned rats (P = 0.42, n/s; Fig. 6A). 
A section-by-section pair-wise comparison was conducted between the lacta-
cystin- and sham-lesioned rats, i.e. S1 of sham controls sacrificed 8 days post-
surgery versus S1 of toxin-lesioned rats sacrificed at the same time-point, etc. 
For rats culled at the first time-point, analysis between the two groups revealed 
an extremely significant difference (S1-6) (***P < 0.0001) that was especially 
prominent between the most rostral PPN sections, while a significant difference 
was also seen between the two groups for a more caudal section, namely S7 (*P 
= 0.025; Fig. 6B). No significant differences were recorded for any of the most 
caudal sections (S8-10), suggesting that PPN regions that lie furthest away from 
the intra-nigral lesion site had not been stimulated to produce the neuropeptide 
galanin.  
The stereology data of lactacystin-lesioned rats that had been sacrificed at 
the later time-point of 35 days post-surgery, also showed highly significant dif-
ferences when comparing sham- to toxin-lesioned rats. These differences were 
particularly prominent for the most rostral sections, with the values representing 
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S1 and S2 which were significantly upregulated in the lesioned rats compared to 
corresponding segments of sham-lesioned rats (***P < 0.0001; Fig. 6C). None 
of the other sections further along the rostro-caudal length of the PPN showed 
any striking differences in terms of number of co-expressing neurons between 
lesioned and non-lesioned rats. However, galanin upregulation persisted within 
the most rostral segments, although less so compared to that seen at 8 days 
post-lesion. In contrast, a similar analysis was conducted to examine the level of 
co-expression within the ipsilateral hemispheres of the lactacystin-lesioned rats 
at both time-points (Figs. 6B, C). This revealed statistically significant differ-
ences between S1-6 (***P < 0.0001) as well as S7 (**P = 0.007). As was ex-
pected, no significant differences were detected between any of the segments in 
the sham-lesioned rats. 
This reveals that the intranigrally administered lactacystin injection that ad-
versely affected cholinergic neurons, resulting in cholinergic cell death (Fig. 4A), 
induces transient upregulation of galanin within PPN cholinergic neurons soon 
after sustaining the lesion, with this effect diminishing substantially at 5 weeks 
following the surgery.  
Discussion 
An animal model where rats are intracerebrally injected with lactacystin, a mi-
crobial metabolite isolated from Streptomyces lactacystinaeu, has shown prom-
ise for being instrumental in unravelling the molecular basis of PD, for testing 
novel therapeutics and for improving existing anti-PD ones (reviewed by Bentea 
et al. 2017). By binding to and inhibiting specific catalytic subunits of the pro-
teasome, lactacystin could determine cell fate and cellular morphology (Orlowski 
1999). Here we used two separate time-points for characterising the progression 
of lactacystin-induced neuronal changes within the rat SNpc and PPN. The first 
 	 22 	
time-point (T1) was at a relatively short period of time following the intranigral 
lesion, to represent an acute phase of lesion development, upon which the rats 
were sacrificed and the brains collected for histological evaluation at 8 days 
post-surgery. T2 represented the second time-point at which a separate set of 
rats were sacrificed at 35 days (5 weeks) post-surgery, thereby representing the 
chronic effects of exposure to the toxin. On the ipsilateral cerebral hemispheres 
of toxin-lesioned animals, at 8 days post-surgery, the toxin had induced a dra-
matic loss of TH-ir SNpc neurons. From this point onwards, the nigral lesion pro-
gressed relatively slowly for the next 4 weeks. The greatest PPN cholinergic neu-
ronal loss occurred between the acute and chronic stage, with these results that 
may suggest that SNpc dopaminergic and PPN cholinergic neurons inherently 
have differential sensitivities to lactacystin. Differential cytotoxic responses were 
shown in our earlier work, with an intranigral infusion of lactacystin that induced 
cell death of both cholinergic and non-cholinergic neurons within the PPN; how-
ever, the non-cholinergic neurons showed increased resistance to the toxic insult 
(Elson et al. 2016). Hence, although this data confirms that the toxin is non-
specific with regards to neuronal type, it suggests strongly that its impact to in-
duce dopaminergic and cholinergic neuronal death follows a different time 
course, possibly due to the activation of different molecular signaling pathways. 
It therefore remains to be discovered how and which specific signal transduction 
pathways are preserved to a greater or lesser extent when exposed to the toxin 
in different neuronal populations. 
As signaling molecules, neuropeptides participate in modulating synaptic 
neurotransmission, with galanin signaling occurring through transmembrane G-
protein coupled receptors (GPCRs) (Branchek et al. 2000). Studies remain 
sparse on whether galanin expressing neurons are affected during progressive 
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PD. Here we reveal, for the first time, that galanin upregulation occurs within 
cholinergic neurons in which cell death pathways have been activated due to the 
stereotaxic intra-nigral infusion of lactacystin. Specifically, examination of the 
stereological distribution data for rats representing T1 revealed that the toxin-
induced lesion adversely affected survival of the PPN cholinergic neurons, but 
that only such neurons locating to the rostral segments of the nucleus, closest to 
the lesion site, underwent cell death. In sham-lesioned rats, galanin expression 
within this cholinergic neuronal population was unaffected by exposure to the 
toxin at either time-point and remained low, in line with previous studies report-
ing on immunohistological mapping of this peptide in non-toxic states (Skofitsch 
and Jacobowitz 1985; Melander et al. 1986).  
When the stereology data on the PPN was arranged topographically, from 
nearest to furthest away from the intra-nigral lesion site, this section-by-section 
comparison showed that galanin is upregulated within PPN cholinergic neurons in 
response to the toxin. In particular, acute toxicity (T1) induced over expression 
of galanin in the PPN cholinergic neurons with this upregulation that proceeded 
as far as S7, compared to sham-lesioned rats. At the more caudal ends of the 
nucleus (furthest away from the intra-nigral lesion site), similar numbers of cho-
linergic neurons expressed galanin than control rats, to further imply that acute 
toxin exposure exerted minimal lethal effects on ChAT-galanin co-expressing 
neurons. In contrast, at the more advanced stage of lesion development (T2), as 
evidence by a greater overall loss of TH- (Fig. 2B) and ChAT-ir neurons (Fig. 
4A), galanin retained upregulation within PPN cholinergic neurons, but at signifi-
cantly lower levels than was seen at the acute time-point. The finding of this 
transient upregulation of galanin within toxin-challenged PPN cholinergic neu-
rons, with this change in expression levels being restricted to segments nearest 
 	 24 	
to the direct insult, indicates that galanin fulfils a neuroregulatory role in PPN 
cholinergic neurons’	response to an irreversible ubiquitin proteasome system in-
hibitor, with a disturbance to the mitochondrial membrane potential and exces-
sive oxidative stress that eventuates to apoptotic cell death (Zhou et al. 2010). 
In this regard, Cordero-Llana and colleagues (2014) revealed the importance of 
galanin for brain plasticity and repair with exogenous galanin resulting in up-
regulation of several pro-survival/pro-neuronal signalling pathways. 
For ongoing characterization of the promising lactacystin rat model of PD, as 
was used in the current study, for mimicking the neuropathology impacting on 
the PPN during progressive PD, future work should continue to develop and vali-
date behavioral test batteries for assessing both motor and non-motor aspects 
relating to the neurodegeneration of the different groups of neurons in the PPN. 
Particular emphasis should be placed on developing readout tools to functionally 
record from the PPN cholinergic neurons, with these neurons being especially 
vulnerable during progressive PD (Hirsch et al. 1987; Rinne et al. 2008; Pienaar 
et al. 2013), which the lactacystin rat model replicates (Pienaar et al. 2015a; 
2015b; Elson et al. 2016). 
Measures such as reference- and working memory tasks for assessing the in-
tactness of recognition memory (Okada et al. 2015), and also spatial memory, 
as is assessed in the Morris water maze (Baxter et al. 2013), have been validat-
ed for interrogating the basal forebrain cholinergic neurons. Similar strides are 
required for developing rodent behavioral measures that show a clear correlation 
between the PPN’s cholinergic neurons, and a rodent’s performance in this task. 
Subjection of lactacystin-lesioned rodents in which galanin has genetically been 
manipulated to be overexpressed, through the creation of transgenic rodent 
lines (for examples, see Pope et al. 2010; Zhang et al. 2012), to such optimized 
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behavioral paradigms, will allow for rescue experiments to determine the capaci-
ty of galanin to restore PPN cholinergic functions which are severely disrupted in 
PD patients (reviewed by Müller and Bohnen 2013). 
The current study also reports on the interesting observation that a distinct 
galaninergic population of neurons that don’t express ChAT, an immunohisto-
chemical marker of cholinergic neurons in the CNS, thus rendering them non-
cholinergic, appears to increase in number within the PPN in this particular neu-
rotoxin model of PD. Although this phenomenon was not quantified in the pre-
sent study, the observation highlights interesting speculation and scope for fu-
ture studies to conduct an in-depth investigation as to the neurochemical identi-
ty of the neurons in which galanin displays upregulated expression following lac-
tacystin lesioning, and how the spatial- and temporal profiles alter as a result of 
such neurotoxicity.  
The PPN is composed of a rich diversity of neuronal cell-types, with three 
major neurochemically distinct neuronal groups that have been identified in the 
PPN, namely cholinergic, GABA (gamma-aminobutyric acid)-ergic and glutama-
tergic neurons, which are heterogeneously distributed along its rostro-caudal ax-
is (reviewer by Pienaar et al. 2016). Glycine immunoreactivity was also reported 
to be present in the human PPN (Pienaar et al. 2013), as well as in various other 
vertebrate species (Fort et al. 1993; Mineff et al. 1998). To further characterize 
the functional properties of the identified non-cholinergic galaninergic population 
of PPN neurons, future studies should characterize their neurochemical pheno-
types in full, as the nature of this interaction between neuropeptides and neuro-
transmitters in a brain system can modulate synaptic neurotransmission by in-
fluencing presynaptic neurotransmitter release, receptor trafficking and recy-
cling, as well as post-synaptic signal coupling (Sallo et al. 2006). Related to this, 
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although the axons of non-cholinergic neurons are more restricted in terms of 
length and number of collaterals, future work should also determine how they 
connect with other brain regions, such as the basal ganglia, thalamus, cortex 
and spinal cord, in normal and pathological conditions. It is possible that such 
identified non-cholinergic galaninergic PPN neurons could also co-express other 
neuropeptides. An example of this is somatostatin, to form part of somatostiner-
gic brainstem neurons, which were shown to form afferent projections to the 
medial pre-optic nucleus, involved in regulating a variety of neuroendocrine pro-
cesses, vegetative functions, sexual behavior, and for modulating the somato-
motoris system (Giehl and Mestres 1995). In this regard, future studies to ex-
plore the relative co-expression levels of galanin with other neuropeptides within 
non-cholinergic PPN neurons, and to characterize the temporal-spatial profile of 
such co-expression during progressive neurodegeneration, as seen in the lacta-
cystin rat model of PD, are warranted. 
The lactacystin rat model used here is an established rat model of PD that 
reflects clinical PPN neuronal damage to a remarkably accurate extent (Pienaar 
et al. 2015a). Using this rat model of PD, our current findings indicate that 
galanin expression levels could play a potentially important role in determining 
clinical manifestations of PD that associate with PPN cholinergic neuronal death, 
which include motor dysfunctions (e.g. gait dysfunction) as well as neuropsychi-
atric disturbances, such as those affecting cognition (reviewed by Pienaar et al. 
2016). Thus far, studies focusing on galanin-ACh interactions have primarily 
done so within the context of AD. Considering that the PPN is a major source of 
cholinergic afferents, and that the nucleus is becoming a prominent target site 
for deep brain stimulation (DBS) as a means for controlling PD-associated gait 
difficulties and postural disturbances (Plaha and Gill 2005; Mazzpone et al. 
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2005; Ferraye et al. 2010), it is surprising that only a limited number of studies 
thus far have explored whether galanin upregulation differs in PPN cholinergic 
neurons, as a result of PD. Our results suggest that galanin receptors could be 
considered potential targets for the development of novel anti-parkinsonian 
therapies. With rodent models being critical tools for furthering understanding as 
to the causes of PD, as well as for identifying novel therapeutics for treating the 
disease, characterising galanin-cholinergic interactions in response to neurotox-
ins associated with PD, remains critical. 
The current work highlights the need for further investigations aimed at bet-
ter understanding the role of galanin in neuroprotecting PPN cholinergic neurons 
against PD-related toxin-mediated cell death and identify the mechanisms by 
which this may be achieved. Lactacystin binds and inhibits specific catalytic sub-
units of the proteasome to induce apoptosis (Orlowski et al. 1999). However, the 
mechanism by which it induces such a cell fate remains a topic of considerable 
investigation. Some studies suggest that this occurs by way of stimulating the 
expression of the death protease, caspase-3 (Li et al. 2015), whilst others re-
vealed that lactacystin triggers a conformational change of B-cell lymphoma 2 
(Bcl-2)-associated X (Bax) protein and that the anti-apoptotic counterpart to Bax 
(members of the Bcl-2 family), can prevent apoptosis by inhibiting the confor-
mational change affecting Bax (Lang-Rollin et al. 2005). 
The current study and our previous work (Pienaar et al. 2015a; 2015b) 
demonstrated that lactacystin offers a suitable model for mimicking the neuro-
pathology affecting the PPN in PD. For investigating the consequences of in-
creased expression of galanin, and in order to determine if such protein upregu-
lation could be deemed neuroprotective against PD-relevant PPN cholinergic neu-
ronal death, future experiments should explore for differential expression and 
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changes in the activity of apoptosis regulatory markers such as capsize3, Bax 
and Bcl-2. Future work should also consider the interacting pathways between 
galanin receptor signalling’s downstream effects and lactacystin-induced im-
paired regulation of protein turnover, oxidative stress, mitochondrial dysfunction 
and the central role that α-synuclein is deemed to play in these processes, which 
converge to cause neuronal dysfunction and ultimately cell death in PD-affected 
brains and in animal model of the disease. In this regard, studies to determine 
for changes in the expression of the galanin receptors GalR1, GalR2 and GalR3 
within cholinergic neurons of the PPN during the lactacystin-induced lesion’s 
progression, could reveal if galanin receptor signaling represent next-generation 
therapeutic targets for the treatment of PD. 
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Figure legends: 
Figure 1. (A) Representative high-power-magnified microscopic images tak-
en with a 20×	air-immersion objective lens of TH-ir neurons within the SNpc of a 
sham-lesioned control rat. DAB served as the chromogen, which is seen here as 
brown cytoplasmic staining. Scale bar: 50 µm. (B) An overlay image consisting 
of a composite average of z-series stacks, collected using confocal microscopy 
equipped with a 20×	objective lens, showing the PPN of a representative lacta-
cystin-lesioned rat. The image reveals ChAT- (red) and galanin-ir (green) neu-
rons, with co-labeled neurons appearing as yellow/orange. Sections were coun-
terstained with DAPI (blue) to visualize nuclei within PPN neurons. White arrow 
heads represent individual neurons immunoreactive for both ChAT and galanin, 
with galanin immunoreactivity that surrounds the nucleus, corresponding to the 
perikaryal cytoplasm. White arrows indicate PPN cholinergic neurons containing 
no galanin, while the yellow arrow shows a galanin-ir neuron within the PPN, 
which was immunonegative for ChAT, and hence a PPN non-cholinergic neuron. 
Scale bar: 20 µm. 
Figure 2. (Ai) A representative photomicrograph of a midbrain coronal sec-
tion showing lactacystin-induced partial (38%) interhemispheric loss of SNpc TH-
ir neurons at 8 (Aii) and 35 days post-surgery (44% neuronal loss) with the SNr 
and VTA that also showed some toxin-induced neuronal damage. The loss of TH-
ir neurons occurs on the side ipsilateral (left) to the stereotaxic needle infusion 
of lactacystin, with no cell loss observed in the contralateral (right) SNpc. Typi-
cally, most damage occurred in closest proximity to the location of the needle 
tip. The degree of TH-ir neuronal loss was less but non-uniform further away 
from the needle tract. The representative image taken of the sham-lesioned con-
trol animal reveals a negligible interhemispheric loss of TH-ir neurons at either 
 	 40 	
(Ai) 8 or (Aii) 35 days post-surgery. Images were captured with a 4×	028 NA 
air objective lens. Scale bar: 20 µm. (B) Stereological quantification of TH-ir 
SNpc neurons reveal neuronal loss unihemispheric to the intra-nigral injection 
site in all toxin-lesioned rats that was statistically extremely significant at both 
the first (***P =089) and second time-point (***P =099) compared to SNpcs of 
control rats. Greater TH-ir neuronal loss was seen in lactacystin-lesioned rats at 
the latter time-point, suggesting a time-dependent progression of the lesion. 
Figure 3. Low-magnification photomicrographs (10×	magnification) of fluo-
rescently-tagged ChAT-ir PPN neurons of rats lesioned with either lactacystin ve-
hicle or the toxin and then sacrificed at 8 or 35 days post-surgery. The images 
were obtained from a single optical section. Scale bar: 300 µm. These repre-
sentative images of control and lesioned rats illustrate that the lesion mainly af-
fected the most rostral segments of the PPN at 8 days post-lesion, whilst at 35 
days post-lesion, lactacystin impacted upon ChAT-ir neuronal viability across the 
rostro-caudal extent of the PPN.   
Figure 4. (A) In serial sections taken from the brains of lactacystin intra-
nigrally injected rats or sham-lesioned controls, unbiased stereological cell 
counts revealed a significant interhemispheric loss of ChAT-ir PPN neurons at 
both 8 (***P < 0.0001) and 35 days (***P < 0.0001) post lactacystin-lesion. 
Neuronal counts are expressed as percentage cell loss on the injected hemi-
spheric side relative to the non-injected hemispheric side, in the same treatment 
group. (B) The typical topographical distribution pattern of ChAT-ir neurons in 
the non-lesioned rat PPN at 8 days post-surgery, with the toxin that had the 
greatest effect on ChAT-ir neuronal counts in more rostral PPN segments. A 
segment-by-segment analysis, comparing sham- to lactacystin-lesioned rats, re-
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vealed the following comparisons to be statistically significant: S1 and S2 (***P 
< 0.0001), S3 (*P =0.039) and S4 (***P < 0.0001). The insert is a schematic 
of the rostro-caudal segmentation of the PPN (S1–S10) in the coronal plane 
which allowed for segment-by-segment comparisons of galaninergic- and cholin-
ergic neurons to be made between the rats (sham- versus lactacystin-lesioned 
and rats sacrificed at T1 versus those at T2). This method is similar to that uti-
lised in our previous work (Pienaar et al. 2015a, b; Elson et al. 2016) to assess 
the expression abundancy of histological markers within PPN neurons across the 
rostro-caudal axis of the PPN. A view is shown of the PPN at -7.92 mm from 
Bregma, according to a commonly used stereotaxic atlas (Paxinos and Watson 
2009), with the approximate positions of major anatomical landmarks which 
provided guidance during sectioning of the PPN. Abbreviations used: Aquaduct, 
Aq; Cuneiform nucleus, Cn; Lateral lemniscus, Ll; Substantia nigra, SN. Scale 
bar: 300 µm. (C) A comparison of the rat groups at 35 days post-surgery re-
vealed that the lesion affected the entire extent of the PPN, although the effects 
were most prominent in rostral segments nearest to the intra-nigral injection 
site. A segment-by-segment analysis, comparing sham- to lactacystin-lesioned 
rats, revealed the following comparisons to be statistically significant: S1 (***P 
=0.0001), S2 (**P =0.007), S3 (***P =0.0001), S4 (**P =0.002), S5 (*P 
=0.046) and S9 (**P =0.004). 
Figure 5. Low-magnification photomicrographs (×10 magnification) taken of 
brain sections containing the PPN, showing the hemispheric side ipsilateral to the 
intra-nigral infusion. Sections were immunofluorescently double-stained for 
ChAT (red) and galanin (green), with representative example images (obtained 
from a single optical section) shown of the rostral, medial and caudal levels of 
the PPN. Digital superimposition of the two colour channels shows the colocal-
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ized areas (orange to yellow). Arrow heads indicate ChAT-galanin-ir neurons. 
Although the vast majority of ChAT-ir neurons were galanin-immunonegative 
under both toxic and control conditions, increased numbers of ChAT-galanin-ir 
neurons were seen in the PPN of rats lesioned with lactacystin compared to 
sham controls, reflected in the stereological counts. Some galanin-ir neurons did 
not co-localise with ChAT-ir PPN ones (arrows). This was observed under both 
lactacystin and sham conditions but more so in the lactacystin-lesioned rats. In 
the PPN region on the lesioned side of toxin-treated rats, densely arranged 
galanin-ir fibers in close proximity to galanin-ir cell bodies was observed during 
both the acute and chronic assessment time-points. Galanin-ir nerve fiber for-
mations were observed far less frequently than in lesioned rats. Scale bar: 500 
µm. 
Figure 6. (A) An extremely significant upregulation in the number of PPN 
cholinergic neurons co-expressing galanin was seen in lactacystin-lesioned rats 
at both time-points, with no data to suggest that such galanin upregulation was 
maintained from T1-T2. Very low levels of such double-stained neurons were 
seen in the PPN of sham-lesioned rats. (B) ChAT-galanin-ir neuronal numbers 
within the ipsilateral PPN were upregulated in lactacystin-lesioned rats, this ef-
fect being most prevalent within the most rostral sections of the PPN. A seg-
ment-by-segment analysis, comparing sham- to lactacystin-lesioned rats, re-
vealed the following comparisons to be statistically significant: S1-6 (***P < 
0.0001) and S7 (*P = 0.025). (C) Topographical distribution of ChAT-galanin-ir 
PPN neurons for the later assessment time revealed only mild galanin upregula-
tion in toxin-lesioned rats, which restricted to the most rostral PPN, closest to 
the SNpc injection site. Galanin levels within cholinergic neurons normalized, 
similar to sham-lesioned rats’	levels, in the medial to most caudal PPN segments. 
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Segmental analysis, comparing sham- to lactacystin-lesioned rats, revealed that 
both S1 and S2 were statistically different (***P < 0.0001). 
